ROKIT Healthcare’s bioprinting-based diabetic foot treatment kit registered as a U.S. FDA medical device

Share this Article

ROKIT Healthcare has completed registration of its Dr. INVIVO-based diabetic foot treatment with the U.S. FDA and has successfully completed clinical studies in the U.S.

Since 2019, the company has conducted clinical studies in India, Korea and Turkey, and based on the most recent study results in the U.S., the treatment has shown promising results in all of the study patients with no side effects.

The company reported that the study subjects were patients of chronic diabetic foot ulcer with an average of 64.4 years of age, 15 years of diabetes duration, and obesity in 90% of the patients.

The principal investigator behind the study is Dr. David G. Armstrong, PhD, DPM, who is Professor of Clinical Surgery at University of Southern California and has produced more than 510 peer-reviewed research papers in scholarly medical journals and 90 book chapters with expertise in the treatment and clinical care of the diabetic foot. Dr. Armstrong is past Chair of Scientific Sessions for the American Diabetes Association’s Foot Care Council and the founder and co-chair of the International Diabetic Foot Conference, the largest annual international symposium on the diabetic foot in the world.

“There is no existing method that resolves chronic diabetic foot ulcers by way of true regenerative medicine, especially for those ulcers that failed to close for many months,” said an official of ROKIT Healthcare. “We have seen our bioprinting-based diabetic foot ulcer treatment offer hope for patients who recovered and got back on their feet within just a few weeks after one procedure, making daily life possible again.

“The clinical study results have demonstrated that ROKIT Healthcare’s diabetic foot ulcer treatment kit can effectively regenerate skin of diabetic foot affected areas regardless of various variables such as race, age, and underlying disease. I can take one more step,” he said.

ROKIT Healthcare’s diabetic foot ulcer treatment, which consists of the printer Dr. INVIVO DFU and patient-specific autologous solution extraction kits, uses 3D scanning and AI-based interpretation of patient wounds to create customized skin regeneration patches.

“Given the FDA medical device registration and several successful global studies yielding promising results, we are proud to be leading a meaningful work of saving human lives with cutting-edge regenerative medicine technologies,” said Seok-Hwan You, CEO of ROKIT Healthcare. “I look forward to contributing to the advancement of chronic ulcer treatment methods and significantly improving the quality of life for patients.”

Share this Article


Recent News

2 Million Parts and Counting: ExOne Adoption Center in Pittsburgh 3D Prints 24/7

AON3D Launches Latest Industrial 3D Printer for High-Temperature 3D Printing



Categories

3D Design

3D Printed Art

3D Printed Guns

3D Printer Reviews


You May Also Like

Markforged Releases Next Gen Metal 3D Printer and Ruggedized 3D Printer

Ahead of its upcoming SPAC merger with one, Markforged has announced new hardware and software releases. The firm says the new Metal X Gen 2, Next Day Metal, and X7...

Featured

Stratasys Lowers Barrier to Entry of Multi-Material 3D Printing with J35 Pro

Stratasys (NASDAQ: SSYS) has been extensively building out its PolyJet line, delivering a series of new 3D printers for just about every vertical you can imagine. Now, the firm has...

Stratasys Releases J5 MediJet 3D Printer for Medical Applications

Stratasys is continuing with its application-specific technology strategy, a plan that Executive Editor Joris Peels has been enthusiastic about, while also warning about the potential drawbacks for some equipment. The...

3D Printing Webinar and Event Roundup: June 6, 2021

We’ve got another busy week of webinars and events, both live and online, to tell you about in this week’s roundup! Topics run the gamut from 3D printing aircraft cabin...


Shop

View our broad assortment of in house and third party products.